Comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: A randomized trial study

Objective: To compare the incidence rate of carboplatin hypersensitivity reactions (HSRs) in gynecologic cancer patients receiving one-hour or two-hour carboplatin retreatment infusions. Setting: A Prospective Randomized Controlled Trial. Methods: Recurrent gynecologic cancer patients 25 to 80-years...

Full description

Saved in:
Bibliographic Details
Main Authors: Weerawich Pornwattanakrilert, Prapaporn Suprasert
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016481651&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/46432
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-46432
record_format dspace
spelling th-cmuir.6653943832-464322018-04-25T07:27:38Z Comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: A randomized trial study Weerawich Pornwattanakrilert Prapaporn Suprasert Agricultural and Biological Sciences Objective: To compare the incidence rate of carboplatin hypersensitivity reactions (HSRs) in gynecologic cancer patients receiving one-hour or two-hour carboplatin retreatment infusions. Setting: A Prospective Randomized Controlled Trial. Methods: Recurrent gynecologic cancer patients 25 to 80-years of age who were scheduled to receive carboplatin retreatment after previously receiving at least six cycles of carboplatin without a history of platinum allergy were invited to enroll. They were randomized to receive either a one-hour or two-hour carboplatin infusion in each cycle. The nurses recorded any occurrence of HSR. Patients who developed carboplatin HSR were discontinued from the study. Results: Forty-five patients were enrolled and randomized to receive either a one-hour carboplatin infusion arm in 69 cycles or a two-hour infusion arm in 67 cycles. Both groups were well balanced regarding median age, body mass index, type of cancer, history of drug allergy, median platinum free interval time, median total number of previous carboplatin cycles, premedication type, regimen and median total dose of carboplatin. Five (3.67%) of the 136 cycles resulted in carboplatin HSR, all of which were Grade 1. Of these, four cycles developed HSR during the one-hour infusion and only one cycle with a two-hour infusion (P = 0.37). The onset of carboplatin HSR occurred within 30-105 minutes after infusion start. Conclusion: Extending the carboplatin infusion time to two hours from one hour did not significantly decrease carboplatin HSR. 2018-04-25T06:54:48Z 2018-04-25T06:54:48Z 2017-02-01 Journal 2476762X 15137368 2-s2.0-85016481651 10.22034/APJCP.2017.18.2.425 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016481651&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/46432
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Agricultural and Biological Sciences
spellingShingle Agricultural and Biological Sciences
Weerawich Pornwattanakrilert
Prapaporn Suprasert
Comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: A randomized trial study
description Objective: To compare the incidence rate of carboplatin hypersensitivity reactions (HSRs) in gynecologic cancer patients receiving one-hour or two-hour carboplatin retreatment infusions. Setting: A Prospective Randomized Controlled Trial. Methods: Recurrent gynecologic cancer patients 25 to 80-years of age who were scheduled to receive carboplatin retreatment after previously receiving at least six cycles of carboplatin without a history of platinum allergy were invited to enroll. They were randomized to receive either a one-hour or two-hour carboplatin infusion in each cycle. The nurses recorded any occurrence of HSR. Patients who developed carboplatin HSR were discontinued from the study. Results: Forty-five patients were enrolled and randomized to receive either a one-hour carboplatin infusion arm in 69 cycles or a two-hour infusion arm in 67 cycles. Both groups were well balanced regarding median age, body mass index, type of cancer, history of drug allergy, median platinum free interval time, median total number of previous carboplatin cycles, premedication type, regimen and median total dose of carboplatin. Five (3.67%) of the 136 cycles resulted in carboplatin HSR, all of which were Grade 1. Of these, four cycles developed HSR during the one-hour infusion and only one cycle with a two-hour infusion (P = 0.37). The onset of carboplatin HSR occurred within 30-105 minutes after infusion start. Conclusion: Extending the carboplatin infusion time to two hours from one hour did not significantly decrease carboplatin HSR.
format Journal
author Weerawich Pornwattanakrilert
Prapaporn Suprasert
author_facet Weerawich Pornwattanakrilert
Prapaporn Suprasert
author_sort Weerawich Pornwattanakrilert
title Comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: A randomized trial study
title_short Comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: A randomized trial study
title_full Comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: A randomized trial study
title_fullStr Comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: A randomized trial study
title_full_unstemmed Comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: A randomized trial study
title_sort comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: a randomized trial study
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016481651&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/46432
_version_ 1681422873488523264